本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

Recursion Pharmaceuticals, Inc.

5.49
+0.920020.13%
盘后5.570.0800+1.46%19:59 EDT
成交量:6,032.27万
成交额:3.19亿
市值:22.34亿
市盈率:-3.02
高:5.52
开:4.72
低:4.71
收:4.57
数据加载中...
2024/12/17

重要事件披露

Form 8-K - Current report
2024/12/11

关联方拟减持公告

Form 144 | RECURSION PHARMACEUTICALS高管Michael Secora拟减持15000股,总价约11.22万美元
2024/12/10

关联方拟减持公告

Form 144 | Recursion Pharmaceuticals 高管 Michael Secora 拟减持15000股,总价约11.63万美元
2024/12/05

关联方拟减持公告

Form 144 | Recursion Pharmaceuticals高管Gibson Christopher拟减持20,000股,总价约14.24万美元
2024/12/04

关联方拟减持公告

Form 144 | RECURSION PHARMACEUTICALS, INC. 高管 Gibson Christopher 拟减持20000股,总价约14.32万美元
2024/12/03

重要事件披露

Form 8-K - Current report
2024/11/27

重要事件披露

Form 8-K/A - Current report: [Amend]
2024/11/26

重要事件披露

Form 8-K/A - Current report: [Amend]
2024/11/21

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/11/20

员工持股计划

Form S-8 - Securities to be offered to employees in employee benefit plans
2024/11/20

重要事件披露

Form 8-K - Current report
2024/11/14

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/11/13

重要事件披露

Form 8-K - Current report
2024/11/13

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/11/13

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/11/13

重要事件披露

Form 8-K - Current report
2024/11/12

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/11/12

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/11/06

重要事件披露

Form 8-K - Current report
2024/11/06

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]